Revelation Biosciences Inc
REVBW0.008USD
0.0000.00%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Revelation Biosciences Inc Company
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).
Revelation Biosciences Inc Info
Ticker SymbolREVBW
Company nameRevelation Biosciences Inc
IPO dateOct 08, 2020
CEOMr. James M. Rolke
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address4660 Lajolla Village Drive
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92122
Phone16508003717
Websitehttps://www.revbiosciences.com/
Ticker SymbolREVBW
IPO dateOct 08, 2020
CEOMr. James M. Rolke
Company Executives of Revelation Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Jennifer A. Carver
Ms. Jennifer A. Carver
Independent Director
Independent Director
--
--
Dr. Lakhmir S. Chawla, M.D.
Dr. Lakhmir S. Chawla, M.D.
Independent Director
Independent Director
--
--
Mr. Jess Roper
Mr. Jess Roper
Independent Director
Independent Director
--
--
Mr. James M. Rolke
Mr. James M. Rolke
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Mr. Chester S. Zygmont, III
Mr. Chester S. Zygmont, III
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Jennifer A. Carver
Ms. Jennifer A. Carver
Independent Director
Independent Director
--
--
Dr. Lakhmir S. Chawla, M.D.
Dr. Lakhmir S. Chawla, M.D.
Independent Director
Independent Director
--
--
Mr. Jess Roper
Mr. Jess Roper
Independent Director
Independent Director
--
--
Mr. James M. Rolke
Mr. James M. Rolke
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Mr. Chester S. Zygmont, III
Mr. Chester S. Zygmont, III
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
21
1.22M
0.00%
-123.67K
2025Q3
20
1.01M
0.00%
-151.99K
2025Q2
18
915.02K
0.00%
-326.06K
2025Q1
22
915.02K
0.00%
-642.43K
2024Q4
23
1.02M
0.00%
-1.09M
2024Q3
24
1.46M
0.00%
-846.13K
2024Q2
25
1.80M
0.00%
-810.44K
2024Q1
25
1.81M
0.00%
-1.39M
2023Q4
25
2.30M
0.00%
-858.80K
2023Q3
24
2.34M
0.00%
-535.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Privium Fund Management BV
--
0%
-44.00K
-100.00%
Sep 30, 2024
Equitec Proprietary Markets, LLC
--
0%
-20.00K
-100.00%
Jun 30, 2024
Susquehanna International Group, LLP
--
0%
-33.47K
-100.00%
Sep 30, 2025
TD Securities (USA) LLC
--
0%
-99.90K
-100.00%
Dec 31, 2024
HRT Financial LP
--
0%
-13.14K
-100.00%
Jun 30, 2025
Clear Street Group Inc
247.43K
0%
+247.43K
--
Sep 30, 2025
TD Securities, Inc.
99.45K
0%
-150.00
-0.15%
Sep 30, 2025
Soltis Investment Advisors, LLC
47.50K
0%
--
--
Sep 30, 2025
Quaker Wealth Management LLC
387.00
0%
--
--
Sep 30, 2025
Clear Street LLC
247.58K
0%
+247.58K
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Revelation Biosciences Inc?
The top five shareholders of Revelation Biosciences Inc are:
Privium Fund Management BV holds 0.00 shares, accounting for 0.00% of the total shares.
Equitec Proprietary Markets, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Susquehanna International Group, LLP holds 0.00 shares, accounting for 0.00% of the total shares.
TD Securities (USA) LLC holds 0.00 shares, accounting for 0.00% of the total shares.
HRT Financial LP holds 0.00 shares, accounting for 0.00% of the total shares.
Privium Fund Management BV holds 0.00 shares, accounting for 0.00% of the total shares.
Equitec Proprietary Markets, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Susquehanna International Group, LLP holds 0.00 shares, accounting for 0.00% of the total shares.
TD Securities (USA) LLC holds 0.00 shares, accounting for 0.00% of the total shares.
HRT Financial LP holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Revelation Biosciences Inc?
The top three shareholder types of Revelation Biosciences Inc are:
Other
Other
How many institutions hold shares of Revelation Biosciences Inc (REVBW)?
As of 2025Q4, 21 institutions hold shares of Revelation Biosciences Inc, with a combined market value of approximately 1.22M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Revelation Biosciences Inc?
In --, the -- business generated the highest revenue for Revelation Biosciences Inc, amounting to -- and accounting for --% of total revenue.
